[HTML][HTML] Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan
M Del Rio, F Molina, C Bascoul-Mollevi… - Journal of Clinical …, 2007 - ncbi.nlm.nih.gov
M Del Rio, F Molina, C Bascoul-Mollevi, V Copois, F Bibeau, P Chalbos, C Bareil, A Kramar…
Journal of Clinical Oncology, 2007•ncbi.nlm.nih.govPurpose In patients with advanced colorectal cancer, FOLFIRI is considered as one of the
reference first-line treatments. However, only about half of treated patients respond to this bi-
therapy, and there is no clinically useful marker that predicts response. A major clinical
challenge is to identify the subset of patients who could benefit from this chemotherapy. We
aimed at identifying a gene expression profile in primary colon cancer tissue that could
predict chemotherapy response.
reference first-line treatments. However, only about half of treated patients respond to this bi-
therapy, and there is no clinically useful marker that predicts response. A major clinical
challenge is to identify the subset of patients who could benefit from this chemotherapy. We
aimed at identifying a gene expression profile in primary colon cancer tissue that could
predict chemotherapy response.
Abstract
Purpose
In patients with advanced colorectal cancer, FOLFIRI is considered as one of the reference first-line treatments. However, only about half of treated patients respond to this bi-therapy, and there is no clinically useful marker that predicts response. A major clinical challenge is to identify the subset of patients who could benefit from this chemotherapy. We aimed at identifying a gene expression profile in primary colon cancer tissue that could predict chemotherapy response.
ncbi.nlm.nih.gov